GGHC
PBYI icon

Gilder Gagnon Howe & Co’s Puma Biotechnology PBYI Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-913
Closed -$218K – 288
2014
Q3 		$218K Buy
+913
New +$187K ﹤0.01% 249

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's PBYI Position: Q4 2014 in Review

Gilder Gagnon Howe & Co sold out of Puma Biotechnology (PBYI) in Q4 2014, closing a stake of 913 shares — an estimated $218K sold.

Gilder Gagnon Howe & Co first reported a position in PBYI in Q3 2014 and held it in 1 quarter. The position peaked at $218K in Q3 2014. 188 funds tracked by Wall St. Rank hold PBYI as of Q4 2014.

  • Gilder Gagnon Howe & Co reported no remaining Puma Biotechnology position as of Q4 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 913 Puma Biotechnology shares in Q4 2014, an estimated $218K.
  • Gilder Gagnon Howe & Co first reported a position in Puma Biotechnology in Q3 2014 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Puma Biotechnology position peaked at $218K in Q3 2014.
  • 188 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2014, filed 13 Feb 2015.